Low dose anti-thymocyte globulin with low dose posttransplant cyclophosphamide (low dose ATG/PTCy) can reduce the risk of graft-versus-host disease as compared with standard-dose anti-thymocyte globulin in haploidentical peripheral hematopoietic stem cell transplantation combined with unrelated cord blood.

ABSTRACT:

SUBMITTER: Xu X 

PROVIDER: S-EPMC7943423 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature